Enteric‐coated mycophenolate sodium in de novo and maintenance kidney–pancreas transplant recipients
暂无分享,去创建一个
[1] J. Medina-Pestana,et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation. , 2009, Transplantation proceedings.
[2] R. Meneses,et al. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. , 2009, Pediatric transplantation.
[3] F. Nevens,et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. , 2009, Transplantation proceedings.
[4] S. Bunnapradist,et al. Impact of gastrointestinal‐related side effects on mycophenolate mofetil dosing and potential therapeutic strategies , 2008, Clinical transplantation.
[5] H. Ekberg. Calcineurin Inhibitor Sparing in Renal Transplantation , 2008, Transplantation.
[6] J. Ehrich,et al. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric‐coated mycophenolate sodium in kidney transplanted children , 2008, Pediatric transplantation.
[7] R. Vijayaraghavan,et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. , 2008, Transplantation proceedings.
[8] K. Hardinger,et al. Adverse drug reaction driven immunosuppressive drug manipulations: a single‐center comparison of enteric‐coated mycophenolate sodium vs. mycophenolate mofetil , 2008, Clinical transplantation.
[9] P. Bolin,et al. Improvement in 3-Month Patient-Reported Gastrointestinal Symptoms After Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients , 2007, Transplantation.
[10] F. Akhlaghi,et al. Effect of Diabetes Mellitus on Mycophenolate Sodium Pharmacokinetics and Inosine Monophosphate Dehydrogenase Activity in Stable Kidney Transplant Recipients , 2007, Therapeutic drug monitoring.
[11] P. Parrilla,et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. , 2007, Transplantation proceedings.
[12] J. Campistol,et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. , 2007, Transplantation proceedings.
[13] N. Davies,et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] L. Rostaing,et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. , 2007, Transplantation proceedings.
[15] E. Hernández,et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. , 2005, Transplantation proceedings.
[16] Y. Seifu,et al. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. , 2005, Transplantation proceedings.
[17] K. Budde,et al. Review of the immunosuppressant enteric-coated mycophenolate sodium , 2004, Expert opinion on pharmacotherapy.
[18] J. Squifflet,et al. EFFICACY AND SAFETY OF TACROLIMUS COMPARED WITH CYCLOSPORINE MICROEMULSION IN PRIMARY SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: 1-YEAR RESULTS OF A LARGE MULTICENTER TRIAL , 2004, Transplantation.
[19] Y. Seifu,et al. Enteric‐Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1‐Year Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] Jeff Maca,et al. Enteric‐Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novo Renal Transplant Patients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] L. Fernández‐Cruz,et al. Native and graft pancreatitis following combined pancreas—renal transplantation , 1993, British Journal of Surgery.
[22] Wolters Kluwer,et al. Enteric-Coated Mycophenolate Sodium A Review of its Use in the Prevention of Renal Transplant Rejection , 2008 .
[23] H. Toz,et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. , 2008, Transplantation proceedings.
[24] M. Salvadori,et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials , 2007, Clinical transplantation.
[25] M. Abbud-Filho,et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. , 2007, Transplantation proceedings.
[26] L. Fernández‐Cruz,et al. Prospective analysis of pancreatic grafts with duplex-Doppler ultrasound: value of resistive index in the diagnosis of rejection. , 1992, Transplant international : official journal of the European Society for Organ Transplantation.
[27] L. Fernández‐Cruz,et al. Duplex-Doppler ultrasonography in monitoring clinical pancreas transplantation , 1988, Transplant international : official journal of the European Society for Organ Transplantation.